Navigation Links
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Date:11/15/2007

umococci, is a growing challenge when it comes to serious infections like CAP," said Dr. Donald Low, Head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology at the University of Toronto in Toronto, Ontario. "Cethromycin, a new antibiotic, may be the solution to this important public health problem, as it has demonstrated a broad spectrum of antibacterial activity and an ability to overcome pneumococcal resistance in clinical trials."

Program Design

The Phase III CAP pivotal development program was comprised of two double-blind, randomized, well controlled, multi-center, multi-national, comparator trials designed to assess the safety and effectiveness of cethromycin in CAP patients compared to Biaxin. Trial CL-06 enrolled patients from clinics in Europe, South America and Israel and Trial CL-05 enrolled patients from the United States, Canada and South Africa. In both trials, cethromycin was evaluated using a 300 mg once-daily oral dosing regimen compared to 250 mg twice-daily dosing for Biaxin, both over a seven-day course of therapy. Biaxin is an FDA-approved standard of care antibiotic currently indicated for the treatment of CAP.

The primary endpoint for both trials was the clinical cure rate at the test-of-cure visit (Day 14-21 post-initiation of dosing). The eligibility of patients for each trial was based on clinical signs and symptoms as well as chest X-ray results as evaluated by an independent radiologist. Extensive electrocardiogram and liver function test monitoring were incorporated into the study design in order to examine safety in these areas and add to the safety database established in previous cethromycin clinical trials.

Results of Trial CL-05

In Trial CL-05, cethromycin met all efficacy endpoints and demonstrated a favorable safety profile as outlined below:

-- Per protocol clinical cure rate (PPc) -- cethromycin 94.0% (205/218)

compared to Biaxin 93.8% (195/208
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
6. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and other ... conference call on Thursday, August 7, 2014 at 11:00 ... second quarter ended June 30, 2014 and to provide ... The second quarter conference call may be accessed ...
(Date:7/29/2014)... GLENWOOD, Ill. , July 29, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... will release financial results for the fiscal third quarter ... 2014. The Company will host a ... at 9:00 a.m. Central Time (10 a.m. Eastern Time). ...
(Date:7/29/2014)... Corporation (NYSE: EW ), the global leader in ... net income for the quarter ended June 30, 2014 of ... income of $94.0 million, or $0.88 per diluted share.  Net ... million, or $0.81 per diluted share, and non-GAAP net income ... Net sales for the quarter ended June 30, 2014 ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25
... Calif., Sept. 13, 2011 Edison Pharmaceuticals, Inc. announced ... Financing. Capital raised will fund US and European approval ... Terms of the financing were not disclosed. ... Pharmaceuticals is a patient- and physician-founded company devoted to ...
... a leader in Quality of Daily Life Solutions announced ... the agreement, Sodexo will offer technology-enabled solutions by Healthsense ... Sodexo,s current offerings to realize their vision of improved ... communities they serve.   Healthsense is an ...
Cached Medicine Technology:Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 Many people complain ... thing they do each morning is put on glasses to ... These same individuals also may be dissatisfied with their ... , Cataracts may cause difficulty driving, especially at night ... follow or find one’s golf ball, see the TV, sew ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 New high ... Medicare Part D by a projected $2.9 to $5.8 ... the actuarial firm Milliman released today by the Pharmaceutical ... D premiums could increase by as much as 8.6 ... C drugs, including Sovaldi and Olysio. , The study ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a three ... throughout that time by picnics, barbecues and beach outings. ... the start of a period that will witness a ... 2012 nearly 1.000 people were killed in crashes involving ... Labor Day. , The summer's warmer weather, longer days ...
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... certain adult autism patients with just a single dose of ... expressions and emotions, Japanese researchers report. Known as the ... in emotional bonding between lovers, and between mothers and their ... in a key area of the brain that has long ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3
... after having their tonsils and adenoids removed to treat ... over time they may relapse or even worsen. African-American ... from Cincinnati Childrens Hospital Medical Center. , Adenotonsillectomy ... from about 19 per 10,000 in Canada to 115 ...
... 14 Murad, where skincare,meets healthcare(R), today ... the,company,s new Vice President of Global Marketing ... pivotal lead in driving brand growth and ... market,opportunities, driving product development, increasing brand profitability,and ...
... Policy Changes in Handling Credit ... ... today that he has reached a settlement with TransUnion over his,lawsuit against ... TransUnion is the first of six credit reporting companies and banks,which ...
... - Body Mass Index (BMI), the measure of a person,s ... effective prognostic tool for specific types of breast cancer, according ... Cancer Center. , The study, published in the March 15 ... breast cancer (LABC) and inflammatory breast cancer (IBC) with high ...
... PHILADELPHIA Women with breast cancer have more aggressive ... or obese, according to findings published in the March ... the American Association for Cancer Research. , The ... disease, said Massimo Cristofanilli, MD, associate professor of medicine ...
... MNKD ), focused on discovering, developing and,commercializing treatments ... at the Cowen and Company Healthcare Conference on March ... Place Hotel in Boston, MA., Interested parties can ... the,presentation in the Investor Relations section of the Company,s ...
Cached Medicine News:Health News:The ABCs of childhood z's: Snoring may be chronic despite surgery 2Health News:Murad, Inc., Hires Lori Jacobus as Vice President of Global Marketing 2Health News:Leukemia Survivor Reaches Landmark Settlement With TransUnion in ID Theft Case 2Health News:Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers 2Health News:Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers 3Health News:Breast cancer more aggressive among obese women 2
Colloidal Gold Conjugated, Protein A - 12 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: